Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma ...

Jim Cramer recently sang praises for Vertex Pharmaceuticals, dubbing it “terrific” and lauding its “revolutionary anti pain ...

Jim Cramer continues to show his support for the biotech company, as evident by his most recent comments from the 14 th of ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. Vertex Pharmaceuticals ( NASDAQ:VRTX – Get Free Report ) last announced its quarterly earnings ...